Revelation Biosciences Inc. One –

SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on the development of immunological therapies for the prevention and treatment of the disease, today announced that the first patient has been enrolled and dosed in a Phase 1b clinical study to assess the potential utility of REVTx-99 for the treatment of patients with allergic rhinitis and patients with chronic nasal congestion without polyps. The clinical study is being conducted in Australia.

“In the United States, approximately 8% of adults and 7% of children have allergies that cause symptoms of allergic rhinitis, also known as hay fever, and patients with allergic rhinitis have a three times higher risk of developing asthma. The risk of developing asthma increases with more severe and persistent allergic rhinitis,” said James Rolke, chief executive of Revelation. “REVTx-99 is being developed as a therapy for the millions of people who suffer from these symptoms each year, including those related to chronic nasal congestion, in which patients with severe cases may require invasive surgery of the nasal passages. sinus. The initiation of patient recruitment is an important step in our efforts to provide patients with safe and effective treatments for these chronic conditions.

The Phase 1b, randomized, double-blind, placebo-controlled, crossover design study is expected to enroll approximately 28 participants. The primary endpoint is to assess the effects of REVTx-99 versus placebo on safety and tolerability. Key secondary endpoints include allergy symptoms (total nasal symptom score) and peak nasal inspiratory flow induced by nasal allergen challenge. The study will have two cohorts: one cohort will receive study drug before nasal allergen challenge (the prophylactic cohort) and the second cohort will receive study drug after nasal allergen challenge (the prophylactic cohort). processing).

The company expects the main data to be released in the first half of 2022.

For more information about Revelation, please visit

About REVTx-99

REVTx-99 is a proprietary intranasal drop formulation under development for the prevention or treatment of viral respiratory infections and is broadly applicable to most infectious viruses including influenza A, influenza B, parainfluenza, rhinovirus , respiratory syncytial virus (RSV), SARS-CoV-2, and its variants. The active ingredient in REVTx-99 stimulates the innate nasal (mucosal) immune system via interaction with the toll-like receptor 4 (TLR4) to produce protective cytokines, including interferons and interferon-related proteins. These protective cytokines work in concert to dampen an invading virus’s ability to proliferate and survive. Phase 1 data showed that REVTx-99 was well tolerated and significantly increased intranasal protective cytokines.

In addition to viral infection, REVTx-99 is also being developed for the management of symptoms of allergic rhinitis and chronic nasal congestion without polyps. REVTx-99 upregulates a protein that competes for the native eotaxin receptor, CCR3, preventing eotaxin from recruiting eosinophils, thereby reducing Th2 cell recruitment and attenuating the allergic response.

About allergic rhinitis

Allergic rhinitis, also known as hay fever, is a very common disorder that affects millions of patients each year and the characteristic complaint of nasal obstruction has a significant impact on quality of life. It is an allergic reaction to tiny particles in the air called allergens. Symptoms include sneezing, nasal congestion, and irritation of the nose, throat, mouth, and eyes. Some treatment options may include antihistamines, anti-inflammatory nasal sprays, anti-leukotrienes, and surgery. Allergic rhinitis can lead to complications in some cases: nasal polyps, sinusitis and middle ear infections. People with severe chronic nasal congestion sometimes need surgery.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunological therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus and RSV. REVTx-99 is also under development for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulatory supplement to be used in combination with intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a home-use rapid diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instruments. .

For more information about Revelation, please visit

Forward-looking statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook” and “project” and similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results may differ materially from those anticipated by the forward-looking statements. statements. Revelation cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: Revelation’s ability to achieve its financial and strategic objectives, due to, among other things, competition; Revelation’s ability to grow and manage the profitability of growth and retain its key employees; the possibility that the Disclosure may be adversely affected by other economic, business and/or competitive factors; risks associated with the successful development of Revelation’s product candidates; the clinical utility of increased intranasal cytokine levels as a biomarker of viral infections; the ability to complete planned clinical studies of REVTx-99; the risks associated with the success of the RVL-CLR01 and RVL-VRL01 clinical studies; the risk that we may not be able to fully enroll our clinical studies or that enrollment may take longer than expected; risks related to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analyzes from our clinical studies; changes in applicable laws or regulations; planned start of clinical studies, schedule of clinical data; the outcome of the clinical data, including whether the results of this study are positive or whether they can be reproduced; the result of the data collected, including whether the results of such data and/or correlations can be reproduced; the timing, costs, conduct and results of our other clinical studies; anticipated processing of future clinical data by the FDA, EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for REVTx-99 and extended indications, REVTx-200, REVDx-501 or any other product candidates; potential indications for which product candidates may be developed; the potential impact that COVID-19 may have on Revelation’s suppliers, vendors, regulatory agencies, employees and global economy; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected length of time Revelation balances will fund its operations; and other risks and uncertainties described herein, as well as the risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company details

Sandra Vedrick
Vice President, Investor Relations and Human Resources
Revelation Biosciences Inc.
E-mail: [email protected]


Chester Zygmont, III
Financial director
Revelation Biosciences Inc.
E-mail: [email protected]

Media contact:
Kristin Faulder
[email protected]


Comments are closed.